title: Immunomodulation of T-cell responses with Vibrio cholerae O135 capsular polysaccharide and its protein conjugate, novel cholera vaccine study models.
abstract: We studied T-cell immune responses to surface capsular polysaccharide (CPS) of Vibrio cholerae O135 and its protein conjugate. CPS and CPS-bovine serum albumin (BSA) activation and presentation are characterized with induced alterations in expression and upregulation of membrane antigens CD25, CD11b, CD16/32, MHCII and CD45 on blood- and spleen-derived T cells. Expression of the early activation marker CD25 revealed efficient CPS-BSA conjugate activation especially of CD4(+) CD3(+)  and CD8(+)  CD3(+)  cells. Specific CPS-BSA-induced CD25(+)  T-cell subsets in blood were observed after the first application, i.e. a 4.2-fold increase of CD4(+) CD25(+)  and 7.6-fold increase of CD8(+) CD25(+)  vs. preimmune levels was determined. The upregulation of surface antigens MHCII and CD45 involved in antigen presentation and cell activation of CD3(+)  cells and their significant reciprocal correlation (R(2)  = 0.92) observed only with CPS-BSA conjugate suggested efficient T-cell dependency and presentation. The pattern of accelerated T-cell activation and engagement of T cells as antigen-presenting cells throughout CPS-BSA immunization contrary to CPS alone was also confirmed in CD4(+) /CD8(+) /CD3(+)  splenic cells. The results revealed different T-cell antigen presentation and activation following administration of CPS and CPS-BSA conjugates, as supported also by evaluation of CD45, MHCII and CD25 expression on CD19(+)  B cells.
authors.affiliation: Slovak Academy of Sciences, Institute of Chemistry, Centre of Excellence GLYCOMED, Bratislava, Slovakia. ema.paulovicova@savba.sk
authors.forename: Ema
authors.initials: E
authors.lastname: Paulovičová
authors.forename: Jana
authors.initials: J
authors.lastname: Korcová
authors.forename: Eva
authors.initials: E
authors.lastname: Machová
authors.forename: Slavomír
authors.initials: S
authors.lastname: Bystrický
mesh_terms: D000818:Animals; D017951:Antigen Presentation; D015703:Antigens, CD / Q000235:genetics / Q000276:immunology; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology; D016667:Bacterial Capsules / Q000276:immunology*; D002771:Cholera / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D022121:Cholera Vaccines / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D015870:Gene Expression; D007114:Immunization; D018796:Immunoconjugates / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D056747:Immunomodulation; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D012710:Serum Albumin, Bovine / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000187:drug effects* / Q000276:immunology; D015854:Up-Regulation; D018074:Vaccines, Conjugate; D014734:Vibrio cholerae / Q000276:immunology*
chemical_list: D015703:Antigens, CD; D022121:Cholera Vaccines; D018796:Immunoconjugates; D018074:Vaccines, Conjugate; D012710:Serum Albumin, Bovine